NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%

Reuters

2025/08/12

NeurAxis Inc. <a href="https://laohu8.com/S/QTWO">Q2</a> 2025: Revenues Surge 46%, Operating Loss Improves by 22%

NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2558364966"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558364966\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558364966?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558364966","market":"nz","top_or_hot":-1,"title":"NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeurAxis Inc. <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-12 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeurAxis Inc. <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRXS","symbol_name":"Neuraxis, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL6GFrXH:1","article_id":"2558364966","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558364966","pubTimestamp":1754996419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic ab","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"NRXS":"Neuraxis, Inc.","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Neuraxis Inc.2025年第二季度：收入飙升46%，运营亏损改善22%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXS":0.9,"NDAQ":0.9},"content_text":"NeurAxis Inc. Q2 2025: Revenues Surge 46%, Operating Loss Improves by 22%\n    \n\n        NeurAxis Inc., a medical technology company, released its financial results for the second quarter of 2025, reporting a significant 46% increase in revenues, amounting to $894 thousand compared to $612 thousand in the same period of 2024. The company also noted a 58% rise in units sold year-over-year, attributed to growth from patients with full insurance reimbursement and a financial assistance program for those without insurance coverage. Operating expenses decreased by 10% compared to the previous year, and the operating loss improved by 22%. NeurAxis highlighted its progress in expanding insurance coverage and commercializing its IB-Stim product. The company recently secured FDA clearance for pediatric treatment of Functional Abdominal Pain and Functional Dyspepsia, expanding its market reach. Additionally, NeurAxis completed a $5 million equity financing round to support its growth strategy, finishing the quarter with a cash balance of $6 million. The company remains optimistic about achieving breakeven in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510194-en) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}